Premium
Efficient Production of Reactive Oxygen Species from Fe 3 O 4 /ZnPC Coloaded Nanoreactor for Cancer Therapeutics In Vivo
Author(s) -
Ong Wee Kong,
Yao Xuemei,
Jana Deblin,
Li Menghuan,
Zhao Yanli,
Luo Zhong
Publication year - 2020
Publication title -
small structures
Language(s) - English
Resource type - Journals
ISSN - 2688-4062
DOI - 10.1002/sstr.202000065
Subject(s) - nanoreactor , reactive oxygen species , in vivo , photodynamic therapy , nanoparticle , photosensitizer , materials science , chemistry , singlet oxygen , nanotechnology , oxygen , photochemistry , organic chemistry , biochemistry , microbiology and biotechnology , biology
While Fe 3 O 4 nanoparticles are frequently exploited for the generation of reactive oxygen species (ROS) in the cancer treatment, its therapeutic performance within a yolk–shell nanostructure for Fenton reaction remains unexplored. To investigate the therapeutic potential, a nanoreactor (YSN@ZnPc@HA) is fabricated by loading zinc phthalocyanine (ZnPc) into a yolk–shell nanocomposite (YSN) consisting of Fe 3 O 4 nanoparticles encapsulated by MgSiO 3 , followed by modifying the silica surface with hyaluronic acid (HA). ZnPc is a typical photosensitizer for photodynamic therapy; Fe 3 O 4 nanoparticles are responsible for Fenton reaction‐based generation of toxic ·OH radicals and also enable magnetic resonance imaging; and HA serves as tumor‐targeting ligand. The obtained YSN@ZnPc@HA is fully characterized by several techniques. Its therapeutic performance is studied both in vitro and in vivo. The experimental results indicate that Fe 3 O 4 nanoparticles in YSN@ZnPc@HA can successfully enhance the therapeutic efficiency of ZnPc by selectively producing ROS in cancer cells. In addition, YSN@ZnPc@HA shows potent T 2 ‐weighted magnetic resonance imaging capacity. These results collectively demonstrate that the YSN@ZnPc@HA nanoparticles can be used as a robust delivery platform for cancer theranostics.